Novo Holdings has led a $100 million Series C financing round for Asceneuron, a Swiss biotech company. This funding aims to advance Asceneuron’s pioneering therapeutics for neurodegenerative diseases, including Alzheimer’s disease and progressive supranuclear palsy (PSP).
Background Information
About Novo Holdings
Novo Holdings is a leading international life science investor, responsible for managing the assets and wealth of the Novo Nordisk Foundation. With a strong focus on creating long-term value, Novo Holdings invests in life science companies at all stages of development. Their portfolio includes significant investments in companies developing innovative treatments for a range of diseases,
